Greenleaf Trust’s Exact Sciences EXAS Stock Holding History

Greenleaf Trust’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,615	Closed	-$246K	–	756
2023 Q2	$246K	Buy	+2,615	New	+$204K	﹤0.01%	658

Other funds holding EXAS

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Greenleaf Trust's EXAS Position: Q3 2023 in Review

Greenleaf Trust sold out of Exact Sciences (EXAS) in Q3 2023, closing a stake of 2,615 shares — an estimated $246K sold.

Greenleaf Trust first reported a position in EXAS in Q2 2023 and held it in 1 quarter. The position peaked at $246K in Q2 2023. 624 funds tracked by Wall St. Rank hold EXAS as of Q3 2023.

Greenleaf Trust reported no remaining Exact Sciences position as of Q3 2023 after selling out during the quarter.
Greenleaf Trust sold 2,615 Exact Sciences shares in Q3 2023, an estimated $246K.
Greenleaf Trust first reported a position in Exact Sciences in Q2 2023 and held it in 1 quarter.
Greenleaf Trust's Exact Sciences position peaked at $246K in Q2 2023.
624 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2023.

Based on Greenleaf Trust's 13F filing for Q3 2023, filed 9 Nov 2023.